Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) EVP David Hallal unloaded 1,349 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $158.00, for a total value of $213,142.00. Following the transaction, the executive vice president now directly owns 118,616 shares of the company’s stock, valued at approximately $18,741,328. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.52% during mid-day trading on Tuesday, hitting $156.46. The stock had a trading volume of 1,300,759 shares. Alexion Pharmaceuticals has a 52-week low of $100.89 and a 52-week high of $185.43. The stock has a 50-day moving average of $161.9 and a 200-day moving average of $161.1. The company has a market cap of $30.950 billion and a price-to-earnings ratio of 79.63.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, July 24th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 38.5% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $5.01 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $183.00.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.